 Kiromic BioPharma Inc NASDAQ: KRBP has announced a strategic pipeline shift to prioritize its allogeneic, non-engineered off-the-shelf product candidate, DeltacelKB-GDT. Kiromic expects to submit its first new investigational new drug IND application to the FDA in 2H of 2022. 